Revlimid

Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
Xtalks
Mon, 02/5/24 - 10:17 am
oncology
cancer
Keytruda
Revlimid
Opdivo
Imbruvica
Darzalex
Merck
Bristol Myers Squibb
AbbVie
Janssen
BMS publishes 'modest' multiple myeloma survival data on heir to Revlimid, Pomalyst
Fierce Biotech
Thu, 08/31/23 - 10:55 am
Bristol Myers Squibb
Revlimid
Pomalyst
Multiple Myeloma
mezigdomide
'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit says
Fierce Pharma
Wed, 11/23/22 - 07:33 am
Bristol Myers Squibb
Celgene
Revlimid
patents
generics
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Fierce Pharma
Thu, 10/27/22 - 11:04 am
Bristol Myers Squibb
generics
Revlimid
Abecma
Breyanzi
Pharma CEOs
Giovanni Caforio
Janssen reports Phase II data for Darzalex-RVd to treat multiple myeloma
Clinical Trials Arena
Mon, 08/29/22 - 10:32 am
JNJ
Janssen
clinical trials
Darzalex
Revlimid
Velcade
Multiple Myeloma
The patent winter is coming
EP Vantage
Wed, 05/25/22 - 10:41 am
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Bristol Myers Squibb's Revlimid finally faces competition in the U.S. with Teva's generic launch
Fierce Pharma
Mon, 03/7/22 - 10:51 pm
Bristol Myers Squibb
Revlimid
Multiple Myeloma
generics
Teva Pharmaceutical
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
Mon, 01/10/22 - 11:49 pm
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more
Fierce Pharma
Mon, 01/10/22 - 11:38 am
JPMHC 2022
Bristol Myers Squibb
Revlimid
Novartis
Moderna Therapeutics
JNJ
Trikafta
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Fierce Pharma
Fri, 12/31/21 - 11:10 am
patents
patent cliffs
Bristol Myers Squibb
Amgen
Pfizer
Revlimid
Eliquis
Enbrel
Otezla
Ibrance
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
Mon, 07/12/21 - 11:08 am
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma—as copycats near
Fierce Pharma
Tue, 06/22/21 - 10:49 pm
Bristol Myers Squibb
Celgene
Revlimid
generics
Sun Pharma
patents
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Fierce Pharma
Thu, 02/4/21 - 08:15 pm
Bristol-Myers Squibb
generics
Revlimid
Zeposia
Reblozyl
Onureg
Congressional investigation reveals Celgene, Teva plotted to keep drug prices high
RAPS.org
Wed, 09/30/20 - 11:08 pm
congress
Celgene
Teva Pharmaceutical
Revlimid
Copaxone
drug pricing
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Motley Fool
Thu, 09/17/20 - 11:09 pm
Bristol-Myers Squibb
Dr Reddy's
Revlimid
Multiple Myeloma
2 newer multiple myeloma drugs fall short in bid for wider market
BioPharma Dive
Tue, 03/10/20 - 11:58 am
Multiple Myeloma
clinical trials
Bristol-Myers Squibb
Takeda
Ninlaro
Empliciti
Revlimid
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Mon, 03/9/20 - 10:52 am
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Motley Fool
Mon, 12/16/19 - 10:41 am
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
The top drugs facing cuts under Pelosi's pricing plan
Biopharma Dive
Fri, 09/20/19 - 10:46 pm
drug pricing
Nancy Pelosi
regulatory
Revlimid
Keytruda
Opdivo
Januvia
insulin
Medicare
How Big Is Celgene's Latest Good News?
Motley Fool
Sun, 08/18/19 - 12:38 pm
Celgene
Otezla
Revlimid
Inrebic

Pages